Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 10/20 | 0.36 |
| ▸ | ARG2 | P78540 | 4/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21245244 | 1.00 | ARG1 (0.36) | ARG1ARG2CHRM2CHRM1CHRM3 | |
| SCHEMBL21244536 | 1.00 | ARG1 (0.36) | ARG1ARG2CHRM2CHRM1CHRM3 | |
| SCHEMBL21244721 | 0.95 | SIGMAR1 (0.37) | ARG1ARG2CHRM2CHRM1CHRM3 | |
| SCHEMBL21275070 | 0.95 | SIGMAR1 (0.37) | ARG1ARG2CHRM2CHRM1CHRM3 | |
| SCHEMBL21244521 | 0.94 | SIGMAR1 (0.40) | ARG1ARG2CHRM2CHRM1CHRM3 | |
| SCHEMBL21244755 | 0.89 | CHRM2 (0.36) | ARG1ARG2CHRM2CHRM1CHRM3 | |
| SCHEMBL21245007 | 0.85 | — | — | |
| SCHEMBL21244660 | 0.85 | — | — | |
| SCHEMBL21274890 | 0.83 | PLG (0.38) | — | |
| SCHEMBL21244964 | 0.83 | PLG (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013741-B1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMA (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-12-14 | — | — | US | disclosed |
| US-11584761-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4013741-A1 | PROCESS OF MAKING CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021030554-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | ARG1 4749/4885ARG2 4611/4885CHRM2 1365/4885 |
| US-11584761-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | ARG1 4749/4885ARG2 4611/4885CHRM2 1365/4885 |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | ARG1 4749/4885ARG2 4611/4885CHRM2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.